MedPath

TRI-V Heart Failure (HF) Implanted Cardioverter Defibrillator (ICD) Study

Not Applicable
Completed
Conditions
Heart Failure
Interventions
Device: Device Implantation
Registration Number
NCT00746135
Lead Sponsor
Abbott Medical Devices
Brief Summary

It's the aim of this study to investigate the impact of Right Ventricular (RV) lead position (RV-apex, His bundle area, RV-apex+His bundle area) in combination with individually optimized Left Ventricular (LV) lead placement and CRT timing on the outcome of cardiac resynchronization therapy (CRT).

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
40
Inclusion Criteria
  • Patient with indication for CRT-D: NYHA III-IV congestive heart failure, in spite of optimal medical treatment for their congestive heart failure
  • LVEDD > 55 mm or > 30 mm/m² BSA
  • EF < 35%
  • Sinus rhythm and one of the following criteria:
  • QRS >= 120 ms and PQ >= 200ms
  • or
  • 2nd / 3rd degree AV block
  • Written informed consent
Exclusion Criteria
  • pacemaker indication (without ICD indication)
  • tricuspidal valve and/or aortic valve replacement
  • Indication for revascularization.
  • less than 3 month after heart surgery or myocardial infarction
  • hypertrophic obstructive cardiomyopathy
  • intravenous catecholamine treatment
  • uncorrected thyroid function
  • severe kidney disorder (creatinin >2,5mg%)
  • no written patient consent
  • insufficient patient compliance
  • participating in another study
  • life expectancy < 1 year due to other severe disease
  • age < 18 years
  • no contraception (young women) or pregnancy

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
BDevice ImplantationAnodal-Cathodal Biventricular Stimulation: cathodal LV Stimulation und anodal RVHis Stimulation = "Anodal-cathodal Bi-V".
ADevice ImplantationConventional Biventricular Stimulation: RV Apex and LV Lead Tip
CDevice ImplantationAnodal-Cathodal Tri-V Stimulation: RV-apex and LV and RV-His
Primary Outcome Measures
NameTimeMethod
Improvement according to Packer's "Heart Failure Clinical Composite Respond"12 months post implant
Secondary Outcome Measures
NameTimeMethod
Intraoperative Increase in Left Ventricular dp/dtAt Implant
QoL assessment("Minnesota Living with Heart Failure = MLHF)12 months
Cardiopulmonary Capacity(Spiroergometry)12 months
2D-echo optimized EF12 months
Change in B-type natriuretic Peptide (BNP)-Concentration12 months
6 min walk test12 months
12 channel ECG12 months
Complications and morbidity12 months

Trial Locations

Locations (1)

Departement of Cardiology - Electrophysiology- Heart Centre Osnabrück - Bad Rothenfelde

🇩🇪

Bad Rothenfelde, Germany

© Copyright 2025. All Rights Reserved by MedPath